März 25, 2026
Regulatorik
How Real-World Data Is Changing Medical Device Evaluation
Why real-world data is starting to reshape decisions about existing medical devices.
Part 3 of the series “The New Rules of Medtech” by Sandra Heeg, Editor-in-Chief, MedTech Media Europe.
Regulatory approval has long been the primary reference point for evaluating a medical device.
Clinical data was generated, performance demonstrated, risks assessed — and based on that evidence, certification was granted. While post-market activities have always been part of the regulatory framework, they often played a secondary role in practice.
This balance is now shifting.
Not because post-market data is new — but because it is increasingly systematically integrated into decisions about existing products.
What has actually changed
Under the EU Medical Device Regulation (MDR), existing requirements have not been fundamentally reinvented, but they have been significantly strengthened and enforced:
- Post-Market Surveillance (Annex III) is now structured and auditable
- Post-Market Clinical Follow-up (Annex XIV) is explicitly required
- Periodic Safety Update Reports (PSUR) are mandatory for many devices
- Clinical evaluation (CER) must be continuously updated
These elements ensure that real-world product performance is no longer just monitored — it is actively evaluated and fed back into regulatory and strategic decision-making.
The new mechanism: data becomes decision-relevant
The key shift is not the existence of data — but its role.
In the past:
- Post-market data → monitoring and vigilance
Today:
- Post-market data → input for concrete decisions, such as:
- updates to clinical evaluation
- refinement of intended use
- additional clinical evidence requirements
- prioritization within product portfolios
Importantly:
These processes do not automatically trigger re-certification, but they can lead to regulatory and strategic actions depending on the findings.
When products actually come back into focus
Relevance typically arises when post-market data indicates:
- clinically significant deviations in performance
- differences across patient populations
- use outside originally defined conditions
- newly identified or underestimated risks
- changes in the benefit-risk balance
In such cases, manufacturers are required to assess:
- whether clinical evaluation needs to be updated
- whether risk management must be revised
- whether regulatory interaction becomes necessary
Practical examples
Imaging AI (Radiology):
Reduced sensitivity in specific subpopulations or dependency on image quality may require updates to clinical evaluation and additional data collection.
Clinical Decision Support:
Differences between predicted and real-world outcomes can lead to revised performance claims and clinical evidence updates.
Connected Monitoring Systems:
New usage patterns and risks identified in real-world use require updates to risk management and PMS activities.
The real shift: decisions move into the lifecycle
Evaluation no longer ends at approval. It becomes part of ongoing product management.
Data is systematically collected, formally assessed, and feeds into real decisions about existing products.
Consequence: products are actively managed
- Clinical evaluation becomes continuous
- Products remain under ongoing assessment
- Portfolio decisions become data-driven
The role of the notified body
Notified bodies are involved during surveillance audits, re-certification, or significant changes. Responsibility for data collection and evaluation remains with the manufacturer.
Conclusion
Approval is no longer the only defining moment. Real-world performance increasingly shapes how medical devices are evaluated.
This marks the transition toward a data-driven product lifecycle, where even established devices may return to focus under defined conditions.
Author: Sandra Heeg
© 2026 Sandra Heeg. All rights reserved. Copyright retained by the author. Publication on medtechmediaeurope.com is permitted by the author and may be withdrawn at any time.